ILUVIEN (fluocinolone acetonide) by Eurofarma Laboratórios is corticosteroid hormone receptor agonists [moa]. First approved in 2014.
Drug data last refreshed Yesterday
ILUVIEN is a corticosteroid implant administered intravitreally for diabetic macular edema and non-infectious uveitis. It works as a corticosteroid hormone receptor agonist to reduce inflammation and edema in the posterior segment of the eye. The implant delivers sustained fluocinolone acetonide directly to the site of inflammation.
Product faces patent expiration in 2.5 years with moderate competitive pressure, suggesting defensive positioning and potential team restructuring in near term.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
Worked on ILUVIEN at Eurofarma Laboratórios? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
Working on ILUVIEN offers experience in a specialized ophthalmic niche with complex healthcare economics, but career trajectory is constrained by approaching LOE and limited commercial scale. Roles focusing on defensive strategies, lifecycle management, and market access are most relevant.